The Role Of Recombinant Human Vascular Endostatin In Postoperative Chemotherapy Of Cardiac Carcinoma

Objective To study the clinical efficacy and safety of recombinant human vascular endostatin combined with nedaplatin and docetaxel in the treatment of advanced cardia cancer.Methods 70 cases of patients admitted to the affiliated hospital of binzhou medical college of shandong province from July 2016 to September 2018 were selected as research objects.All of them were diagnosed as advanced cardia cancer by postoperative pathology.The patients were divided into experimental group(35 cases)and control group(35 cases)by random number table method.Both groups were treated with 4 cycles of chemotherapy of nidaplatin plus docetaxel,and the experimental group was treated with recombinant human vascular endostatin combined with nidaplatin plus docetaxel.Follow-up was conducted every 2 months after the end of the chemotherapy cycle,and data such as serum tumor markers,disease-free survival period,survival time,survival rate and so on were recorded and sorted.Results There was no significant difference between the recombinant human vascular endostatin group and the conventional chemotherapy group in terms of gender,age,degree of tumor differentiation and number of lymph node dissection(P>0.05).Compared with the control group,there was no statistically significant difference between the experimental group and the control group in blood changes,heart function,liver function,skin reaction and other adverse reactions(P>0.05).There were 13 cases(37.14%)of hematogenous metastasis in the experimental group and 22 cases(62.86%)in the control group,and the difference was statistically significant(P<0.05).The chi-square test of positive vasocarcinoma thrombus and lymph node staging trend showed a difference and linear correlation between the two groups(2=18.31,r=0.422,P=0.001).The survival rate without disease progression 12 months after surgery was 88.60%in the experimental group and 62.91%in the control group,and the difference was statistically significant(2=6.41,P=0.01).Conclusion Recombinant human vascular endostatin combined with docetaxel plus nedaplatin in the treatment of postoperative patients with cardiac cancer can effectively reduce the blood metastasis,improve the postoperative progression-free survival rate at 12 months,and the short-term efficacy is not affected,safe and effective.